We have located links that may give you full text access.
Recent Developments in Nanomaterial Drug Delivery and Upgrading Treatment of Cardiovascular Disease.
Current Pharmaceutical Design 2023 November 2
Cardiovascular diseases (CVDs) are a leading cause of death and disability worldwide. Given the current challenges in recognizing and managing CVDs, the initial and long-term outcomes of patients vary substantially despite recent breakthroughs in the treatment of CVDs. Due to a deficiency of cutting-edge diagnostics and individually targeted treatments, innovative and out-of-the-box strategies are required to close this chasm. Nanotechnology allows the development of nanomaterials with the potential to enhance health and treat disease. Particularly, nanotechnologies have recently come to be seen as having a future for the management of chronic illnesses including cancers and cardiovascular disorders (CVDs). Nanoparticle drug carriers, which have the potential to increase the pharmaco-efficiency and safety of conventional treatments, are an area of great interest. The use of nanomaterials as drug carriers in CVDs has been proposed in a number of different ways, but there are now ongoing debates on which nanomaterials and nanoformulation should be used. Accordingly, the focus in the current study is on the application of nanoparticles to cardiovascular diseases and the administration of medications using nanomedicine.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app